ArticleAmerican journal of cardiovascular disease2012
New frontiers in heart hypertrophy during pregnancy.
Article in American journal of cardiovascular disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 56 citations in OpenAlex.
- Parity and heart failure risk in diabetic women with coronary artery disease: a multicentre cohort study.ESC heart failure · 2026Article
- From bump to pump: extracellular matrix remodeling, dynamics, and biomechanics in the maternal heart.American journal of physiology. Heart and circulatory physiology · 2026Review
- Review
- Late vs. Early Preeclampsia.International journal of molecular sciences · 2025Review
- The role of mechanosignaling in the control of myocardial mass.American journal of physiology. Heart and circulatory physiology · 2025Review
- Placental transcriptome variation associated with season, location, and urinary prenatal pyrethroid metabolites of Thai farm-working women.Environmental pollution (Barking, Essex : 1987) · 2024Article
- Exosomes: current knowledge and future perspectives.Tissue barriers · 2024Review
- Stromal Cell-SLIT3/Cardiomyocyte-ROBO1 Axis Regulates Pressure Overload-Induced Cardiac Hypertrophy.Circulation research · 2024Article
- Hypertension Related Co-Morbidities and Complications in Women of Sub-Saharan Africa: A Brief Review.Circulation research · 2024Review
- Coordinated Metabolic Responses Facilitate Cardiac Growth in Pregnancy and Exercise.Current heart failure reports · 2023Review
- Effects of pregnancy on electrocardiographic, vasovagal tonus index, and echocardiographic variables in horses.Veterinary world · 2023Article
- Made in the Womb: Maternal Programming of Offspring Cardiovascular Function by an Obesogenic Womb.Metabolites · 2023Review
- Evidence of Nitric Oxide Impairment During Hypertensive Pregnancies.Advances in experimental medicine and biology · 2023Review
- Metabolic signatures of pregnancy-induced cardiac growth.American journal of physiology. Heart and circulatory physiology · 2022Article
- Serotonin receptor subtype-2B signaling is associated with interleukin-18-induced cardiomyoblast hypertrophy in vitro.Asian biomedicine : research, reviews and news · 2022Article
- Ventricular wall stress and wall shear stress homeostasis predicts cardiac remodeling during pregnancy: A modeling study.International journal for numerical methods in biomedical engineering · 2022Article
- Multiscale simulations of left ventricular growth and remodeling.Biophysical reviews · 2021Review
- Uterine Vascular Control Preconception and During Pregnancy.Comprehensive Physiology · 2021Article
- Exosomes in Cardiovascular Diseases: Pathological Potential of Nano-Messenger.Frontiers in cardiovascular medicine · 2021Review
- Downregulated expression of microRNAs associated with cardiac hypertrophy and fibrosis in physiological pregnancy and the association with echocardiographically-evaluated myocardial function.Biomedical reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
During Pregnancy, heart develops physiological left ventricular hypertrophy as a result of the natural volume overload. Previously we have characterized the molecular and functional signature of heart hypertrophy during pregnancy. Cardiac hypertrophy during pregnancy is a complex process that involves many changes including in the signalling pathways, composition of extracellular matrix as well as the levels of sex hormones. This review summarises the recent advances and the new frontiers in the context of heart hypertrophy during pregnancy. In particular we focus on structural and extracellular matrix remodelling as well as signalling pathways in pregnancy-induced physiological heart hypertrophy. Emerging evidence shows that various microRNAs modulate key components of hypertrophy, therefore the role of microRNAs in the regulation of gene expression in pregnancy induced hypertrophy is also discussed. We also review the role of ubiquitin proteasome system, the major machinery for the degradation of damaged and misfolded proteins, in heart hypertrophy. The role of sex hormones in particular estrogen in cardiac remodeling during pregnancy is also discussed. We also review pregnancy-induced cardiovascular complications such as peripartum cardiomyopathy and pre-eclampsia and how the knowledge from the animal studies may help us to develop new therapeutic strategies for better treatment of cardiovascular diseases during pregnancy. Special emphasis has to be given to the guidelines on disease management in pregnancy.
Indexed as
Identifiers
22937489PMC3427979W20548What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.